ESMO China Voice | Prof. Jiayu Wang: MAIC Analysis Highlights the Potential of Bireociclib as a Second-Line Therapy for HR+/HER2– Advanced Breast Cancer, Offering a New Treatment Option for Patients 

ESMO China Voice | Prof. Jiayu Wang: MAIC Analysis Highlights the Potential of Bireociclib as a Second-Line Therapy for HR+/HER2– Advanced Breast Cancer, Offering a New Treatment Option for Patients 

2025.11.05
In the second-line treatment of hormone receptor–positive, HER2-negative (HR+/HER2–) advanced breast cancer, CDK4/6 inhibitors combined with fulvestrant have become the standard of care. However, variations in efficacy and safety profiles among different inhibitors remain an important clinical consideration.
ESMO Hot Topic | Professor Zhao Yanxia: PATINA Trial PRO Data Confirm Palbociclib Combination Extends PFS Without Compromising Quality of Life

ESMO Hot Topic | Professor Zhao Yanxia: PATINA Trial PRO Data Confirm Palbociclib Combination Extends PFS Without Compromising Quality of Life

2025.11.05
The PATINA (AFT-38) trial is a randomized, open-label, phase III study designed to evaluate the efficacy and safety of palbociclib + HER2-targeted therapy + endocrine therapy versus HER2-targeted therapy + endocrine therapy alone in patients with HR+/HER2+ metastatic breast cancer following induction therapy. Previous data from PATINA demonstrated that the addition of palbociclib significantly prolonged median progression-free survival (mPFS) in this patient population.
ESMO Hot Topic | Professor Zhang Juliang: Long-Term GeparNuevo Follow-Up Reveals Durable Survival Benefits from Durvalumab Neoadjuvant Therapy in Early Triple-Negative Breast Cancer 

ESMO Hot Topic | Professor Zhang Juliang: Long-Term GeparNuevo Follow-Up Reveals Durable Survival Benefits from Durvalumab Neoadjuvant Therapy in Early Triple-Negative Breast Cancer 

2025.11.05
At the 2025 ESMO Annual Congress, the long-term follow-up results of the GeparNuevo trial (Abstract #292MO) were presented. The data showed that although durvalumab combined with neoadjuvant chemotherapy did not significantly improve the pathological complete response (pCR) rate, it significantly prolonged survival outcomes, including invasive disease-free survival (iDFS), distant disease-free survival (DDFS), and overall survival (OS). Notably, among patients who achieved pCR, the 7-year OS rate reached 100% in the durvalumab group, suggesting that immunotherapy may provide long-term benefits through sustained immune surveillance. Oncology Frontier invited Professor Zhang Juliang from Xijing Hospital, Air Force Medical University, to comment on these findings and discuss strategies for optimizing immunotherapy in early triple-negative breast cancer (TNBC).
ESMO Hot Topic | Professor Li Huiping: monarchE Trial OS Results Announced — A New Breakthrough in Adjuvant Therapy for HR+/HER2- High-Risk Early Breast Cancer 

ESMO Hot Topic | Professor Li Huiping: monarchE Trial OS Results Announced — A New Breakthrough in Adjuvant Therapy for HR+/HER2- High-Risk Early Breast Cancer 

2025.11.05
At the 2025 ESMO Annual Congress, the overall survival (OS) data from the monarchE trial were released, showing that abemaciclib combined with endocrine therapy significantly improved survival in patients with HR+/HER2- high-risk early breast cancer, reducing the risk of death by 15.8%.
CSCO Experts’ Insights │ Professor Fangjian Zhou: Guideline Updates and Quality Control System Drive China’s Renal Cancer Care to the Global Forefront

CSCO Experts’ Insights │ Professor Fangjian Zhou: Guideline Updates and Quality Control System Drive China’s Renal Cancer Care to the Global Forefront

2025.11.03
From September 10 to 14, 2025, the 28th Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) was held in Jinan, Shandong. With the theme “Standardizing Diagnosis and Treatment, Leading Innovation”, the conference brought together leading domestic and international scholars. The Renal Cancer session featured the highly anticipated release of the 2025 CSCO Renal Cancer Guidelines, setting a new standard for improving treatment outcomes and promoting standardized care across China. Following the conference, Oncology Frontier – Urology Frontier invited Professor Fangjian Zhou from Sun Yat-sen University Cancer Center to discuss the groundbreaking advances in renal cancer management and the quality-control experience of the Guangdong Cancer Center.